Blocking the receptor for endothelin lowers novel cardiovascular risk factors in patients with chronic kidney disease independent of blood pressure, according to a new study. The findings suggest that blocking the receptor may provide heart-related benefits to these patients. Sixty million people globally have chronic kidney disease.